Institute of Biomedical Research Corp.
MRES · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.27 | -0.05 | -0.52 | 0.00 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -30.88 | 15.08 | -29.53 | 0.00 |
| Quality | ||||
| ROIC | -28.75% | -70.38% | -203.98% | 0.00% |
| Gross Margin | 43.25% | 18.97% | 29.46% | 0.00% |
| Cash Conversion Ratio | 0.85 | 0.92 | 0.02 | 0.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.90% | – | – | – |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.02 | -0.07 | 0.01 | 0.00 |
| Interest Coverage | -49.18 | -49.03 | -14.68 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.49 | 1.23 | 3.84 | 0.00 |
| Cash Conversion Cycle | 511.72 | 588.02 | 943.60 | 0.00 |